2026年9月16日•3 分钟阅读
Korea Serb... TipsoBoc (Ivosidenib) Begins Price Negotiation for IDH1‑Mutant Cholangiocarcinoma Reimbursement
TipsoBoc (ivosidenib) from Korea Serb... has entered health‑insurance price negotiations for IDH1‑mutant locally advanced or metastatic cholangiocarcinoma after passing the benefits evaluation committee in July.